To see the effects of vitamin D in addition to anti-tubercular treatment on inter-leukin 6 levels in patients having pulmonary tuberculosis

Not Applicable

• Conditions: Health Condition 1: A15- Respiratory tuberculosis

• Registration Number: CTRI/2022/02/040458
• Lead Sponsor: Department of pulmonary medicine GMCH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 4 April 2022

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

a) Freshly confirmed cases of pulmonary tuberculosis (by smear microscopy/CBNAAT).

(b) Age > 18years

Exclusion Criteria

a) Pulmonary TB patients with other respiratory co-morbidities like co-infections,COPD, lung cancer and interstitial lung disease.

(b) Disseminated TB

(c) Hemodynamically unstable patients

d) Patients who are taking vitamin D supplementation, oral corticosteroids or otherImmunosuppressants or drugs known to interfere with vitamin D levels orinterfere with anti- tubercular drugs (phenytoin, phenobarbital, carbamazepine,theophylline) will be excluded from the study.

(e) Patients having extra pulmonary TB, Human Immunodeficiency Virus (HIV) infection,hepatic disease, renal failure, malignancy, pregnancy, sarcoidosis, hyperparathyroidismand history of hypercalcemia will be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To see effects of vitamin d supplementation on interleukin 6 levelsTimepoint: To see effects of vitamin d supplementation after 2 months

Secondary Outcome Measures

Name	Time	Method
To see effects of vitamin d supplementation on sputum smear negative conversion rateTimepoint: after 2 months of vitamin D supplementation